Clinical Trial Update: Efficacy and Safety of PRC-4016 in Subjects With Mixed Dyslipidemia [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating PRC-4016 for mixed dyslipidemia was terminated. The update provides status but does not include trial results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia

Drugs mentioned

• PRC-4016

Snippet

Sponsor: Pronova BioPharma | Conditions: Dyslipidemia | Phase 2 | Status: TERMINATED